Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2008 3
2009 6
2010 8
2011 8
2012 9
2013 8
2014 18
2015 10
2016 18
2017 20
2018 22
2019 13
2020 23
2021 19
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.
Yamasaki T, Saeki I, Yamauchi Y, Matsumoto T, Suehiro Y, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Takami T, Chayama K, Kato N, Sakaida I. Yamasaki T, et al. Among authors: hiramatsu a. Liver Cancer. 2022 Feb 22;11(4):329-340. doi: 10.1159/000522389. eCollection 2022 Jul. Liver Cancer. 2022. PMID: 35978601 Free PMC article. Review.
Reply from the authors.
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kawaoka T, et al. Among authors: hiramatsu a. Hepatol Res. 2020 Dec;50(12):1393. doi: 10.1111/hepr.13578. Hepatol Res. 2020. PMID: 33280200 No abstract available.
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Morio K, Moriya T, Naeshiro N, Nonaka M, Aisaka Y, Azakami T, Hiramatsu A, Aikata H, Oka S. Amioka K, et al. Among authors: hiramatsu a. Cancers (Basel). 2022 Oct 16;14(20):5066. doi: 10.3390/cancers14205066. Cancers (Basel). 2022. PMID: 36291850 Free PMC article.
Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report.
Tamura Y, Kawaoka T, Aikata H, Namba M, Fujii Y, Morio K, Murakami E, Yamauchi M, Hiramatsu A, Nakahara T, Imamura M, Maruhashi T, Kobayashi T, Ohdan H, Kimura T, Nagata Y, Arihiro K, Chayama K. Tamura Y, et al. Among authors: hiramatsu a. Clin J Gastroenterol. 2020 Jun;13(3):421-427. doi: 10.1007/s12328-019-01075-6. Epub 2019 Nov 28. Clin J Gastroenterol. 2020. PMID: 31782114 Review.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Amioka K, et al. Among authors: hiramatsu a. Cancers (Basel). 2022 Jan 10;14(2):320. doi: 10.3390/cancers14020320. Cancers (Basel). 2022. PMID: 35053484 Free PMC article.
Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia.
Daijo K, Kawaoka T, Nakahara T, Nagaoki Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Hara K, Tajima G, Kobayashi M, Chayama K. Daijo K, et al. Among authors: hiramatsu a. Clin J Gastroenterol. 2017 Aug;10(4):383-387. doi: 10.1007/s12328-017-0753-0. Epub 2017 Jun 9. Clin J Gastroenterol. 2017. PMID: 28597413
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C, Uchikawa S, Kawaoka T, Kinami T, Yano S, Amioka K, Naruto K, Ando Y, Yamaoka K, Tsuge M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Kouno H, Kohno H, Morio K, Moriya T, Nonaka M, Aisaka Y, Masaki K, Honda Y, Naeshiro N, Hiramatsu A, Aikata H, Oka S. Kikugawa C, et al. Among authors: hiramatsu a. Oncology. 2024;102(3):239-251. doi: 10.1159/000533859. Epub 2023 Sep 20. Oncology. 2024. PMID: 37729889
A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
Yoshikawa Y, Imamura M, Yamaoka K, Kosaka Y, Murakami E, Morio K, Fujino H, Nakahara T, Okamoto W, Yamauchi M, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Fujitaka K, Arihiro K, Hattori N, Chayama K. Yoshikawa Y, et al. Among authors: hiramatsu a. Clin J Gastroenterol. 2021 Feb;14(1):283-287. doi: 10.1007/s12328-020-01287-1. Epub 2020 Nov 16. Clin J Gastroenterol. 2021. PMID: 33200345
Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibody.
Hatooka H, Shimomura Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Makokha GN, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Aikata H, Tanaka S, Chayama K. Hatooka H, et al. Among authors: hiramatsu a. J Infect. 2022 Mar;84(3):391-399. doi: 10.1016/j.jinf.2021.12.025. Epub 2021 Dec 23. J Infect. 2022. PMID: 34953905
159 results